NCT02447328 2021-09-05
A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
AstraZeneca
Phase 4 Completed
AstraZeneca
Eli Lilly and Company